Related references
Note: Only part of the references are listed.Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry
J. H. Salmon et al.
RMD OPEN (2015)
Late-onset neutropenia following rituximab treatment for rheumatologic conditions
Gabriel S. Breuer et al.
CLINICAL RHEUMATOLOGY (2014)
Late-onset Neutropenia in Patients with Rheumatoid Arthritis after Treatment with Rituximab
Rita Abdulkader et al.
JOURNAL OF RHEUMATOLOGY (2014)
Low- Versus High-Dose Rituximab for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Markus Bredemeier et al.
ARTHRITIS CARE & RESEARCH (2014)
Rituximabe para o tratamento da artrite reumatoide: Revisão sistemática
Lívia Lovato Pires de Lemos et al.
Revista Brasileira De Reumatologia (2014)
Cerebral Toxoplasmosis After Rituximab Therapy
Gilles Safa et al.
JAMA INTERNAL MEDICINE (2013)
Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center
E. Besada et al.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2012)
Late-Onset Neutropenia Following Rituximab Therapy in Rheumatic Diseases: Association With B Lymphocyte Depletion and Infections
Daniel Tesfa et al.
ARTHRITIS AND RHEUMATISM (2011)
Neutropenia associated with rituximab therapy
Cliona Grant et al.
CURRENT OPINION IN HEMATOLOGY (2011)
Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms
Daniel Tesfa et al.
EXPERT REVIEW OF HEMATOLOGY (2011)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials
Ronald F. van Vollenhoven et al.
JOURNAL OF RHEUMATOLOGY (2010)
New therapies for treatment of rheumatoid arthritis
Josef S. Smolen et al.
LANCET (2007)
A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study
E. Nitta et al.
ANNALS OF ONCOLOGY (2007)
Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma
Kenji Fukuno et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action
MD Pescovitz
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Share Paper
